We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01327235
First Posted: April 1, 2011
Last Update Posted: August 1, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jiangsu Simcere Pharmaceutical Co., Ltd.
  Purpose
The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.

Condition Intervention Phase
Malignant Pleural Effusion Malignant Ascites Drug: Endostar Drug: Cisplatin Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Multicenter Trial of Endostar and/or Cisplatin in Patients With Malignant Pleural Effusion or Ascites

Resource links provided by NLM:


Further study details as provided by Jiangsu Simcere Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Objective Response Rate [ Time Frame: baseline to measured progressive disease, every three weeks ]
    WHO criteria


Secondary Outcome Measures:
  • Time to Progression [ Time Frame: baseline to every three weeks until disease progression ]
  • Quality of Life [ Time Frame: baseline to every three weeks ]
  • Incidence of Adverse Events [ Time Frame: Up to 1 month after the last treatment ]

Enrollment: 336
Study Start Date: March 2011
Study Completion Date: July 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Endostar Drug: Endostar
intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
Active Comparator: Cisplatin Drug: Cisplatin
cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
Experimental: Endostar and Cisplatin Drug: Endostar
intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
Drug: Cisplatin
cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological or cytological diagnosis of thoracic or abdominal tumor
  • At least medium amount of malignant pleural effusion or ascites
  • ECOG Performance Status 0-2
  • Life expectancy ≥ 2 months
  • Adequate hematologic, cardiac, renal, and hepatic function
  • No major surgery within 4 weeks prior to this study
  • Written informed consent

Exclusion Criteria:

  • Patients with central nervous system (CNS) metastases
  • Evidence of bleeding diathesis, serious infection
  • Evidence of myocardial infarction, unstable angina or cardiac insufficiency
  • Presence of serious COPD and/or respiratory failure
  • Allergic to study drug
  • Pregnant or lactating women
  • Participation in other clinical trials within 30 days prior to this study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01327235


Locations
China
The 81st Hospital of Chinese PLA
Nanjing, China
The Affiliated Hospital of Medical College, QingDao University
Qingdao, China
Fudan University Shanghai Cancer Center
Shanghai, China
Sponsors and Collaborators
Jiangsu Simcere Pharmaceutical Co., Ltd.
Investigators
Principal Investigator: Shukui Qin, MD The 81st Hospital of Chinese PLA
  More Information

Responsible Party: Jiangsu Simcere Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT01327235     History of Changes
Other Study ID Numbers: SIM-90
First Submitted: March 28, 2011
First Posted: April 1, 2011
Last Update Posted: August 1, 2014
Last Verified: July 2014

Additional relevant MeSH terms:
Pleural Effusion
Ascites
Pleural Effusion, Malignant
Pleural Diseases
Respiratory Tract Diseases
Pathologic Processes
Pleural Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Cisplatin
Antineoplastic Agents